TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

The Motley Fool Logo The Motley Fool By Josh Kohn-Lindquist
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Renaissance Group initiated a new $35.11 million position in Halozyme Therapeutics, acquiring 478,735 shares representing 1.32% of its U.S. equity assets. The biotech company offers innovative drug delivery technology and has demonstrated strong financial performance with consistent sales growth.

Insights
ESAIY   positive

Collaborative partner in successful cancer therapy trial


HALO   positive

Strong financial metrics including 38% annual sales growth over the last decade, 47% net income margin, successful licensing model, and consistent stock performance outpacing S&P 500